Immunome (IMNM) Enterprise Value (2020 - 2026)

Immunome (IMNM) has 8 years of Enterprise Value data on file, last reported at -$582.7 million in Q1 2026.

• Quarterly Enterprise Value fell 83.63% year-over-year to -$582.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$582.7 million (down 83.63% YoY) and the FY2025 annual result came in at -$653.5 million, down 200.72% from the prior year.
• Enterprise Value advanced to -$582.7 million in Q1 2026, from -$653.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$20.3 million in Q4 2022 to a low of -$653.5 million in Q4 2025.
• A 5-year average of -$210.4 million and a median of -$217.3 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 58.72% — and 2024, when it plunged 624.52%.
• Tracing IMNM's Enterprise Value over 5 years: stood at -$20.3 million in 2022, then tumbled by 579.73% to -$138.1 million in 2023, then tumbled by 57.3% to -$217.3 million in 2024, then plunged by 200.72% to -$653.5 million in 2025, then gained by 10.83% to -$582.7 million in 2026.
• The last three Enterprise Value figures came in at -$582.7 million (Q1 2026), -$653.5 million (Q4 2025), and -$272.6 million (Q3 2025), per Business Quant data.